Assessment of Vertical Pattern in Correlation With Third Molar Inclusion : A 3D CBCT Analysis
Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Mar 19, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain facial and jaw characteristics relate to the presence of impacted third molars, also known as wisdom teeth. Researchers want to understand if the position of these teeth is connected to the shape and growth patterns of a person's jaw and face. They will analyze patients using advanced imaging techniques to look at both the horizontal and vertical aspects of their jaw structure.
To participate in this study, individuals must be at least 18 years old and have at least one impacted third molar that is fully developed. Some people may not be eligible if they have had previous jaw surgeries, certain medical conditions, or other dental issues. If you join the study, you will undergo imaging tests that help the researchers gather information about your teeth and jaw. This research aims to improve our understanding of how impacted wisdom teeth relate to facial structure, which could help in planning better treatments for patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • CMV stage 5 on lateral radiography (end of growth)
- • at least one impacted third molar at minimum Nolla stage 6 development
- Exclusion Criteria:
- • Previous maxillofacial trauma
- • Growing patients
- • Missing permanent tooth or early avulsion
- • Dysplasia
- • Dentofacial deformities
- • Endocrinological pathologies with implications for maxillofacial growth
- • Syndromes
- • History of maxillofacial or orthognathic surgery
- • History of orthodontic treatment
- • Incomplete data
About Central Hospital, Nancy, France
Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nancy, , France
Patients applied
Trial Officials
Bart VANDE VANNET, PhD
Study Director
Central Hospital, Nancy, France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported